Summary Survival analysis of 144 histologically confirmed cases of colon carcinoma diagnosed in a 12 year period at the Tampere University Hospital was performed to test the hypothesis that p53 overexpression is associated with a poor clinical outcome. Immunohistochemical staining of paraffin-embedded sections using a polyclonal antibody CM-1 against p53 protein was performed to identify aberrant expression of the p53 tumour-suppressor gene. Si'xty-nine per cent of the tumours (100/144) showed overexpression of the p53 protein. The prevalence of p53 overexpression was independent of age and sex of the patient and subsite of the tumour, but was slightly, although not statistically significantly, higher in advanced than in localised tumours. Overexpression was associated with a higher S-phase fraction. Some indication of a larger proportion of aneuploid tumours among those with overexpression was also observed, although this finding did not reach statistical significance. Significantly reduced patient survival for tumours with p53 overexpression was found. Patients with p53-overexpressing tumours had a corrected 5 year survival rate of 37% compared with 58% among patients whose tumours had normal expression of p53. The corresponding 10 year rates were 34% and 54%. In the multivariate analysis using a Cox model, the survival difference was independent of age and sex of the patient, as well as of subsite and stage of the tumour. Furthermore, the effect of p53 overexpression remained after controlling for flow cytometric parameters in an analysis of a subset of tumours. Thus, p53 overexpression appears to be a useful prognostic indicator in colon carcinoma.
chromosome 17 (Hollstein et al., 1991; Levine et al., 1991) . In normal cells, the p53 protein regulates transcription of several genes and, thus, cell proliferation and differentiation.
It has been shown to arrest the cell cycle at GI phase (Kastan et al., 1991; Lin et al., 1992) and induce apoptosis (Shaw et al., 1992) in response to DNA damage. A gene that is probably an important mediator of its effects has recently been identified (El-Deiry et al., 1993) .
The levels of p53 protein in normal cells and tissues are extremely low because of the protein's short half-life, and are undetectable by standard immunohistochemical staining (Rodriguez et al., 1990) . Most forms of mutations result in the formation of an abnormal protein with novel oncogenic properties and prolonged half-life (Finlay et al., 1988) . The accumulation of such mutated protein in the tumour cell nuclei can be detected by immunohistochemical staining (Scott et al., 1991) . This does not apply to frameshift and chain-terminating (nonsense) mutations, which do not result in elevated p53 protein content. However, these constitute less than 20% of all mutations in human cancers (Hollstein et al., 1991) .
Some indication of the prognostic significance of the mutations or resulting protein overexpression has been reported in colon carcinoma (Kern et al., 1989; Remvikos et al., 1992; Starzynska et al., 1992; Sun et al., 1992) and other cancers (Ostrowski et al., 1991; Isola et al., 1992; Martin et al., 1992; Quinlan et al., 1992; Thor et al., 1992; Visakorpi et al., 1992) .
In this study, we analysed the effect of immunohistochemically detectable p53 overexpression on the long-term survival in an unselected series of colon carcinoma patients. All slides were evaluated in a blinded fashion, i.e. without knowledge of the clinical outcome of the patients.
The immunohistochemical assay for p53 protein overexpression in paraffin-embedded tissues has been validated in our previous studies Visakorpi et al., 1992) . The T47D cell line, which is a breast cancer cell line with a well-documented p53 mutation (Bartek et al., 1990) , was used as a positive control. The T47D cells were fixed with buffered formalin for 24 h, dehydrated with acetone and pelleted in fluid paraffin (60'C) in test tubes. These blocks were mounted and stained similarly to the clinical samples. The normal colonic tissue was used as a negative control.
DNA flow cytometry was performed on dewaxed, rehydrated and trypsin-treated 50 lum sections of paraffinembedded tumours as previously descnbed (Kallioniemi et al., 1991 A clear survival advantage was observed for patients with tumours with normal p53 expression (10 year cumulative corrected survival rate 54%, 95% CI 38-68%) as compared with patients with p53-overexpressing tumours (34%, 95% CI 25-43%) (Figure 2 ). In stage-specific analyses, the absolute difference in the 10 year survival rate between tumours with p53 overexpression and normal p53 expression was larger among patients with lalised (47% vs 68%) than with non-localised tumours (20% vs 29%) (Table I) .
When age and subsite were controLld for simultaneously, the prognostic effect of p53 overexpression remained significant (Table II) . After additional adjustment for stage, the effect of p53 overexpression was reduced by approximately half. Adjustment for sex was not used because there were no sex differences in the relative risk of death.
In the subset of tumours (n = 93) with information available on both p53 expression and DNA flow cytometry, adjustment for DNA index and S-phase fraction did not reduce the prognostic signifi of p53 overexpression (Table Ill) (Baker et al., 1989; Nigro et al., 1989; van den Berg et al., 1989; Kawasaki et al., 1992) .
In 1992, the first report on the effect of the p53 mutations on colon cancer survival was published (Sun et al., 1992) , and other reports soon followed (Remvikos et al., 1992; Starzynska et al., 1992) . In all the published studies, p53 mutation or overexpression was associated with poor prognosis. However, the Swedish report published by Sun et al. (1992) was the only one in which a reasonable number of patients (>50) were followed up for at least 5 years and multivariate analysis of survival was used. We were able to demonstrate survival differences in cause of death-specific 10 year survival rates, i.e. to make extensive use of the information on cause of death stated in the death certificates. Furthermore, our study is the first one to assess p53 overexpression in association with flow cytometry in a multivariate survival analysis.
The method of p53 protein staining employed in all studies is quite similar, although different antibodies have been used. However, Sun et al. (1992) found a prognostic effect for cytoplasmic p53 protein, but not for nuclear p53 protein. In Overexpression of the p53 gene, assessed by nuclear staining of its protein product, was an indicator of poor long-term survival in our study, especialy in localised tumours. The prognostic signifi of p53 overexpression was independent of age and sex of the patient, but more evident among patients with tumours of the proximal than distal colon.
In our study, the S-phase fraction of tumours overexpressing p53 was significntly higher than that of tumours without accumulation of p53 protein. This suggests that the effect of p53 overexpression leads to acceleration of cell proliferation. However, adjustment for DNA flow cytometrc findings did not diminish the prognostic significnce of p53 overexpression, which suggests that changes in the cell cycle are not the only mechanism contributing to high malignant potential associated with the p53 overexpression. According to our results, p53 overexpression does not have a clear prognostic effect among tumours with high proliferative activity. It is possible that the tumours with normal p53 protein content, but an elevated S-phase fraction, have undergone mutation of some other oncogene or tumoursuppressor gene, which could explain the poor prognosis of patients with such tumours. The identification of other mechanisms contributing to the metastatic potential of colonic carcinomas would be of interest, since the survival of patients with metastatic colon cancer in our study was poor irresptive of p53 expression.
Our results suggest that stage of disease is still the strongest prognostic factor available (even though only TNM staging was used) and that p53 overexpression can be used as an additional prognostic indicator. However, by combining the two factors more accurate prediction of disease outcome is feasible, e.g. the 10 year survival rate among all patients with localised disease was 54%, but the could be divided into two distinct groups on the basis of p53 overexpression (with survival rates of 68% vs 47%).
The fact that the effect of p53 overexpression is most marked in localised tumours suggests that p53 overexpression may be useful for identification of patients at high risk of recurrence and who may thus benefit from more radical treatment approach and intensive medical follow-up after the primary treatment. Correspondingly, improved prognostic prediction may benefit patients with a low nrsk of disease progression by allowing avoidance of unnecessary colostomy or adjuvant chemotherapy.
